CA
NZ
UK
AU
IND
US
No company announcement dated October 14, 2026 was identified as the cause of the 5.52% gain. Recent verified developments centre on collaborations: Halozyme had disclosed five new agreements through July, including Vertex’s April deal with a USD 15 million upfront payment for Hypercon, a …
No company announcement dated October 14, 2026 was found to explain the 4.81% gain. At USD 20.04, the stock was about 33.6% above its USD 15.00 IPO price, based on simple arithmetic. It is still a recent listing: Nasdaq Global Market trading began on …
No company announcement dated October 14, 2026 was found to account for the 4.75% rise. Only 8,767 shares had traded, against 70,842,844 shares outstanding on June 30, 2026, so a small number of orders could determine the last quoted price without indicating broad investor …
No company announcement dated October 14, 2026 was found to explain GENB’s 4.44% gain. The stock opened 2.90% above its prior close, according to published market data. Generate Biomedicines sold 25 million shares at USD 16.00 in its IPO. Its lead programme, GB-0895, is …
No announcement dated October 14, 2026 was found to account for the 4.08% advance. At USD 24.48, the shares were about 44% above the USD 17.00 IPO price by simple calculation. Alamar listed on the Nasdaq Global Select Market after an upsized offering led …
No company announcement dated October 14, 2026 was identified, so the 4.03% rise appears to follow the August 5 second-quarter report rather than a fresh event. Caris reported approximately 59,200 clinical cases, up around 18%, and more than 114,000 whole-exome and whole-transcriptome tests. Gross …
No announcement dated October 14, 2026 was found, so the 3.95% rise follows the August 10 quarterly update rather than a newly reported event. Auvelity net sales increased to USD 180.3 million from USD 119.6 million. Sunosi generated USD 35.8 million, including USD 1.5 …
No announcement dated October 14, 2026 was located to explain the 3.85% price gain, so the context remains the company’s earlier financial and regulatory developments. Research and development expense rose to USD 394.9 million from USD 224.1 million, while general and administrative expense increased …
No company announcement dated October 14, 2026 was found, so the 3.78% rise appears to follow the August 11 second-quarter report. Zura is developing tibulizumab, an antibody designed to act on the BAFF and IL-17 pathways, in two Phase 2 programmes. General and administrative …
No company release dated October 14, 2026 was identified, and an analyst action mentioned in the market feed could not be confirmed. The 3.59% gain therefore has no verified single trigger. In the August 18 report, Immatics said its anzu-cel cell therapy, which targets …
Please wait processing your request...